Alternative Mechanisms of Multidrug Resistance in Cancer

1. Front Matter

   Pages i-xii

   PDF

2. Mechanisms of Multidrug Resistance

   • John A. Kellen

   Pages 1-30

3. The Role of Glutathione S-Transferases in Drug Resistance

   • William T. Bellamy

   Pages 31-65

4. Pharmacology of Drug Transport in Multidrug Resistant Tumor Cells

   • Henk J. Broxterman, Carolien H. M. Versantvoort

   Pages 67-80

5. The Multidrug Resistance-Associated Protein — MRP

   • Dominic Fan, Diane R. Bielenberg, Yun-Fang Wang, Robert Radinsky, Pedro J. Beltran

   Pages 81-94

6. Topoisomerases in Multidrug Resistance

   • Teruhiro Utsugi, Cynthia E. Herzog, Dominic Fan

   Pages 95-120

7. Genotoxicity of Topoisomerase II Inhibitors: Consequences for Chemotherapy

   • Frank Gieseler

   Pages 121-133

8. A Distinctive Multiple Drug Resistance Phenotype Expressed by Tumor Cells Following Exposure to X-Irradiation

   • Bridget T. Hill

   Pages 135-152

9. Taxoids and Multidrug Resistance

   • Robert A. Newman, Dominic Fan

   Pages 153-171

10. The Contribution of Protein Kinase C to Multiple Drug Resistance in Cancer

    • Catherine A. O’Brian, Nancy E. Ward, Krishna P. Gupta, Karen R. Gravitt

    Pages 173-190

11. BCL-2 and Chemoresistance in Cancer

    • John C. Reed

    Pages 191-214

12. Molecular Interrelationships in Multidrug Resistance

    • John A. Kellen

    Pages 215-223

13. Mechanisms of Cisplatin Resistance and Its Reversal In Human Tumors

    • Hironori Ishida, Hiroshi Kijima, Yukinori Ohta, Mohammed Kashani-Sabet, Kevin J. Scanlon

    Pages 225-264

14. Perspectives

    • John A. Kellen

    Pages 265-273

15. Conclusions

    • John A. Kellen

    Pages 275-278

16. Back Matter

    Pages 279-281

    PDF

Nullius in verba. . . Truth will be tested not by words. Horace (Epistles) Few read introductions except for book reviewers, who want to take a shortcut and avoid reading the book itself. However, tradition requires that the preface make public why the book was written at all (this is not supposed to include powerful reasons such as augmenting the ego of the editor and authors). Frequently, the inflationary tendency to publish in verbose length is in conflict with market forces and interest. No doubt, multidrug resistance is a "fashionable" topic, but there are many fashions displayed on the cat-walk of scientific literature. One can rationalize that the forces driving our concern with multi drug resistance reflect the frustration of pharmaceutical companies and oncologists alike: as soon as a new anticancer drug enters clinical trials, cancer cells start eluding extinction with their elaborate and successful mechanisms. Many grants have been awarded and spent, only to confirm the futility of our efforts to defeat this cellular Darwinism. Our medical and scientific training makes it hard, if not impossible, to accept that the survival of a malignant cell, alone or as part of a tissue, is part of the continuance of life. Since exposure to noxious and lethal substances is unavoidable, cells have been forced to develop a multitude of mechanisms to prevent entry or accelerate exit of such materials from intracellular space.

• Cancer
• Drugresearch
• Pharmacology/Biology
• carcinoma
• chemoresistance
• antibacterial drug resistance

• Sunnybrook Health Science Center, University of Toronto, Toronto, Canada

  John A. Kellen

Policies and ethics